ATLANTA, GA – – (Globe Newswire – September 2, 2026) – – A shareholder class action lawsuit has been filed against Hims & Hers Health, Inc. (“Hims”) (NYSE: HIMS). The lawsuit alleges that Defendants made false and misleading statements and/or failed to disclose material adverse facts, including allegations that: (1) Hims shared consumers’ health information with third-party advertising platforms; (2) Hims charges consumers for prescriptions almost immediately after they submit an intake form, despite telling consumers that they will be able to consult with a medical provider to find a treatment that is “right for them;” (3) the foregoing conduct subjected Hims to regulatory scrutiny; (4) as a result of the foregoing, Hims was reasonably likely to incur fees and penalties; and (5) as a result of the foregoing, Defendants’ positive statements about Hims’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

 If you purchased Hims shares between August 4, 2025 and July 29, 2026 and experienced a loss on that investment, you are encouraged to discuss your legal rights by contacting Marshall P. Dees, Esq. at mdees@holzerlaw.com, by toll-free telephone at (888) 508-6832, or by visiting the firm’s website at www.holzerlaw.com/case/hims-hers-health/ for more information.

The deadline to ask the court to be appointed lead plaintiff in the case is November 2, 2026.